[1] CROUT T M,PARKS L P,MAJITHIA V. Neuromyelitis optica (Devic’s syndrome): an appraisal[J].Curr Rheumatol Rep,2016,18(8): 54. [2] BERNARD-VALNET R,LIBLAU R S,VUKUSIC S,et al.Neuromyelitis optica:A positive appraisal of seronegative cases[J].Eur J Neurol,2015,22(12): 1511-1518,e82-83. [3] RINGELSTEIN M,METZ I,RUPRECHT K,et al.Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder[J].Mult Scler,2014,20(7): 882-888. [4] 韩冰,朱辉,刘晶瑶.AQP4与NMO-IgG在视神经脊髓炎谱系疾病发病机制中的作用[J].中风与神经疾病杂志,2017,34(11):1045-1046. [5] SON M,KIM D,PARK K S,et al.Detection of aquaporin-4 antibody using aquaporin-4 extracellular loop-based carbon nanotube biosensor for the diagnosis of neuromyelitis optica[J].Biosens Bioelectron,2016,78: 87-91. [6] TRADTRANTIP L,ZHANG H,SAADOUN S,et al.Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica[J].Ann Neurol,2012,71(3): 314-322. [7] KUROSAWA K,MISU T,TAKAI Y,et al.Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody[J].Acta Neuropathol Commun,2015,3: 82. [8] PHUAN P W,ANDERSON M O, TRADTRANTIP L,et al.A small-molecule screen yields idiotype-specific blockers of neuromyelitis optica immunoglobulin G binding to aquaporin-4[J].J Biol Chem,2012,287(44):36837-36844. [9] NAGELHUS E A,OTTERSEN O P.Physiological roles of aquaporin-4 in brain[J].Physiol Rev,2013,93(4): 1543-1562. [10] 谢屿平,卢娉霞,曹颖平.视神经脊髓炎免疫学发病机制研究进展[J].国际检验医学杂志,2019,40(1):107-111. [11] SAINI H,FERNANDEZ G,KERR D,et al.Differential expression of aquaporin-4 isoforms localizes with neuromyelitis optica disease activity[J].J Neuroimmunol,2010,221(1/2): 68-72. [12] PISANI F,SPARANEO A,TORTORELLA C,et al.Aquaporin-4 autoantibodies in neuromyelitis optica: AQP4 isoform-dependent sensitivity and specificity[J].PLoS One,2013,8(11): e79185. [13] 黄华生,高玉娟,韦仕荣,等.视神经脊髓炎谱系疾病缓解期修饰治疗的研究进展[J].卒中与神经疾病,2016,23(4):293-298. [14] LEVIN M H,BENNETT J L,VERKMAN A S.Optic neuritis in neuromyelitis optica[J].Prog Retin Eye Res,2013,36: 159-171. [15] CARPANINI S M,TORVELL M,MORGAN B P.Therapeutic inhibition of the complement system in diseases of the central nervous system[J].Front Immunol,2019,4(10):362. [16] KUMAR R,PAUL B S,SINGH G,et al.Therapeutic efficacy of plasma exchange in neuromyelitis optica[J].Ann Indian Acad Neurol,2018,21(2):140-143. [17] 张玉凤,杨佳.血浆置换在神经脊髓炎相关视神经炎中的应用效果及影响因素分析[J].临床和实验医学杂志,2018,17(21):2319-2323. [18] MIYAZAKI-KOMINE K,TAKAI Y,HUANG P,et al.High avidity chimeric monoclonal antibodies against the extracellular domains of human aquaporin-4 competing with the neuromyelitis optica autoantibody,NMO-IgG[J].Br J Pharmacol,2016,173(1): 103-114. [19] TALLANTYRE E C,WHITTAM D H,JOLLES S,et al.Correction to: Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation[J].J Neurol,2018,265(5):1123. [20] MORROW M J,WINGERCHUK D.Neuromyelitis optica[J].J Neuro Ophthalmol,2012,32(2):154-166. [21] BIENIA B,BALABANOV R.Immunotherapy of neuromyelitis optica[J].Autoimmune Dis,2013:741490. [22] BONNAN M,VALENTINO R,OLINDO S,et al.Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder[J].Mult Scler,2009,15(4):487-492. [23] HUANG T L,LIN K H,WANG J K,et al.Treatment strategies for neuromyelitis optica[J].Ci Ji Yi Xue Za Zhi,2018,30(4):204-208. |